Introduction
============

The Notch pathway is a major intercellular short-range coordination mechanism highly conserved throughout evolution and similar in all multicellular organisms from invertebrates to mammals ([@B17]). Notch designates a trans-membrane receptor encoded by a gene originally identified as that responsible for the appearance of a 'notch' in the wings of *Drosophila melanogaster*. In mammals, four Notch receptors, 1--4, and five canonical ligands, Jagged 1--2 and Delta-like (DLL) 1,3 and 4, have been identified as membrane-spanning proteins ([@B11]).

The mechanism of Notch signaling does not exploits the classical signal transduction pathways of most surface receptors: upon ligand binding, the surface metalloprotease ADAM10 clips the Notch extracellular domain just outside the plasma membrane and releases an extracellular Notch fragment which remains bound to its ligand and is then endocytosed by the ligand-bearing cell, which in turn undergoes signaling. Then, the inner membrane protease γ--secretase cleaves the Notch intracellular domain (NICD), the active form of Notch, which is released in the cytoplasm, migrates to the nucleus and binds to CSL transcription factors (also known as RBP-Jκ) regulating Notch target gene expression ([@B11]). The encoded proteins regulate further expression of many downstream genes, some of which can either maintain the cell in an uncommitted state or induce differentiation, while others regulate cell proliferation and apoptosis ([@B22]). The increasing interest in Notch pathway ad a key regulator of cell function and differentiation has been paralleled by the development of appropriate methods and tools for its investigation in cellular and animal models, as exhaustively reported in a recent review ([@B36]).

In Vertebrates, Notch signaling is physiologically involved in embryo development and morphogenesis which exploit its ability to mediate intercellular communication. In fact, the formation of distinct organs and tissues requires adhesion mechanisms which promote and maintain the sorting of different cell populations. In post-natal life, Notch signaling is maintained as a key mechanism of cell--cell communication and its dysregulations are implicated in tumor development and metastasis and in non-neoplastic pathological conditions such as ischemic and fibrotic diseases, sometimes playing a dual role as pathogenic mechanism or adaptive/compensatory response ([@B12]; [@B14]). In this context the heart, whose complex assembly requires the precise coordination of diverse cells, represents an appropriate paradigm to understand the roles of the Notch pathway in health and disease.

Notch Pathway in the Developing and Diseased Heart
==================================================

Notch signaling is a key mechanism of normal heart morphogenesis, being required for the formation of the atrioventricular canal and valves, outflow tract and coronary vessels, and for growth and differentiation of the endocardium, myocardium and epicardium ([@B13]; [@B21]). Among the cellular mechanisms operating during cardiac morphogenesis, Notch signaling has been shown to mediate epithelial-mesenchymal transition (EMT) of endocardial precursor cells: in particular, Notch signaling down-regulates surface cadherin expression and disables intercellular adhesion among these cells, allowing them to move, reach the atrio-ventricular and outflow tract regions, and pattern the cardiac valves ([@B33]). Moreover, during growth and three-dimensional organization of the ventricular myocardium, Notch signaling is required to sustain cardiomyocyte precursor proliferation and differentiation as well as compaction of the primitive trabecular myocardium ([@B13]; [@B21]). Finally, the Notch pathway is crucial for coronary vasculogenesis, namely the formation of primary vascular rudiments from the epicardial mesenchyme, and angiogenesis, namely the sprouting of new vessels from pre-existing ones. Both phenomena are regulated by vascular endothelial growth factor (VEGF), whose downstream pathway involves Notch/Jagged up-regulation by endothelial cells ([@B8]). Notch signaling appears a homeostatic regulator of the endothelium, since it can mediate either proliferation and resistance to apoptosis during active angiogenesis or contact inhibition and cell cycle arrest during blood vessel stabilization. In this latter phase, Notch also favors the recruitment of pericytes from the mesenchyme and stimulates growth, migration and resistance to apoptosis of vascular smooth muscle cells, thereby promoting the build-up of functional blood vessels ([@B29]).

The pivotal role of the Notch pathway in heart morphogenesis emerges from both studies on Notch or Jagged1 knock-out mice and clinical reports, showing that defective Notch signaling is correlated with cardiac malformations such as Tetralogy of Fallot in Alagille syndrome, aberrant bicuspid aortic valve and left ventricular non-compaction cardiomyopathy ([@B13]; [@B21]). In the adult heart, Notch signaling between mature cells is absent under physiological conditions but can be roused to take part in the protective response to injury, as later discussed.

Another morphogenetic effect of the Notch pathway with major repercussions on the adult diseased heart is the regulation of stromal cell differentiation and extracellular matrix (ECM) production ([@B15]). In the embryo, Notch signaling promotes EMT and generates mesenchymal cells: in turn, these cells differentiate into different stromal cell lineages, including the cardiac valves and coronary endothelium. Although in adult tissues EMT is suspected to play some role in the generation of new fibroblasts and myofibroblasts, the main pro-fibrotic cells, during the development of organ fibrosis ([@B15]), the existing evidence suggests that Notch signaling can rather exert anti-fibrotic effects on the diseased heart, for instance by counteracting the pro-fibrotic cytokine transforming growth factor (TGF)-β and reducing myofibroblast proliferation ([@B24]).

Notch Pathway in the Ischemic Heart
===================================

Myocardial infarction (MI), one of the leading causes of death worldwide, mainly depends on coronary artery occlusion and ischemia followed by reperfusion (I/R), in which blood flow restoration is accompanied by oxidative stress exacerbating myocardial damage. Noteworthy, the adult myocardium can re-express fetal genes as an adaptive response to injury: in this context, increased Notch1 signaling was demonstrated in surviving cardiomyocytes of the MI border zone ([@B10]). Several studies have shown that Notch signaling protects the heart from I/R-induced myocardial injury: activation of Notch1 pathway limits the extent of ischemic damage, promotes coronary neo-angiogenesis and revascularization of the ischemic myocardium, reduces myocardial fibrosis and improves heart function ([@B10]; [@B18]; [@B19]; [@B9]). Conversely, in systemic Notch1 deficient mice, I/R leads to the development of a larger myocardial infarct area and worsening of heart function than wild-type controls ([@B19]).

Notch1 plays an important role in the protection of ischemic myocardium during pre- (IPC) and post-conditioning (IPost), well-known adaptive responses of the heart to increase its resistance to I/R injury ([@B38]). Notch1 pathway is activated during myocardial IPC and IPost and leads to reduction of cardiomyocyte apoptosis, infarct size and contractile impairment. Conversely, inhibition of Notch1 signaling by N1ICD knockdown abrogates IPC- and IPost-induced cardioprotection ([@B40]).

The mechanisms underlying Notch-mediated cardio-protection are complex and involve an interplay between mature and immature cardiomyocytes, cardiac progenitors cells (CPCs) and bone marrow (BM)-derived cells (**Figure [1](#F1){ref-type="fig"}**). Notch1 prevents cardiomyocyte apoptosis by activation of PI3K/AKT pro-survival signaling and regulation of apoptotic genes ([@B18]; [@B25]; [@B40]). Moreover, Notch signaling induces cell cycle re-entry of immature cardiomyocytes ([@B5]; [@B31]), promotes proliferation and myogenic differentiation of CPCs ([@B3]), decreases oxidative/nitrosative stress ([@B25]) and prevents cardiac fibrosis ([@B6]).
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Recent studies indicate that Notch1 is ineffective in promoting cardiac regeneration in adults due to permanent epigenetic modifications at the Notch-responsive promoters which render their transcriptional repression irreversible ([@B7]). Consistently, in cardiac-specific Notch1 deficient mice, the loss of Notch1 in post-natal cardiomyocytes did not affect the severity of myocardial injury ([@B19]). Hence, the beneficial effects of Notch1 re-activation previously observed in transgenic animals ([@B18]) could be mediated *via* other cell types, such as CPCs and BM-derived cells. Accordingly, Notch1 recruits BM-derived mesenchymal stem cells (MSCs) in the infarction border zone, promoting proliferation and preventing apoptosis ([@B19]). Moreover, transplantation of N1ICD-overexpressing MSCs reduces -- while that of Notch1-deficient MSCs increases -- both infarct size and contractile impairment ([@B19]). Overall, these findings suggest that the maintenance or reactivation of Notch signaling in cardiac cells can be a therapeutic target to protect against myocardial damage.

Notch Pathway in Cardiac Fibrosis
=================================

Cardiac fibrosis, a late complication of many heart diseases, can occur as myocardial replacement fibrosis to prevent cardiac rupture, for instance after MI, or as interstitial fibrosis without cardiomyocyte loss, an adaptation to chronic injury by functional overload, ischemia and cardiomyopathies. Started as compensatory to organ damage, cardiac fibrosis becomes maladaptive and dysfunctional in the long term ([@B27]; [@B34]). In general, fibrosis results from an imbalance between ECM synthesis and degradation by fibrogenic cells, chiefly myofibroblasts. In response to pro-inflammatory and pro-fibrotic mediators up-regulated in cardiac injury, among which TGF-β1 plays a major role, resident cardiac fibroblasts, CD45+ hemopoietic stromal cells and, perhaps, EMT-derived fibroblasts, vascular pericytes and immune cells are recruited and prompted to differentiate into myofibroblasts, characterized by dual immunophenotypical and ultrastructural features of fibroblasts and smooth muscle cells ([@B1]; [@B16]; [@B26]). Myofibroblast contraction and excess ECM deposition cause the distortion of the normal myocardial architecture. Moreover, myofibroblasts secrete a variety of mediators which stimulate autocrine cell activation and fibrogenesis and exert paracrine effects on the cells nearby, causing chronic inflammation and further cardiomyocyte dysfunction ([@B34]).

Several studies have shown that Notch signaling is involved in counteracting cardiac fibrosis, primarily via inhibition of myofibroblast differentiation. In particular, the expression of Notch1, 3, and 4 are down-regulated during fibroblast--myofibroblast transition in neonatal hearts, while Notch signaling inhibition promotes myofibroblast formation ([@B6]). Consistently, in a mouse model of pressure overload, Notch1 controlled the balance between fibrotic and regenerative repair by inhibiting myofibroblast proliferation and promoting mobilization and expansion of cardiac muscle precursor cells ([@B24]). Recently, *in vivo* intramyocardial delivery of hydrogels containing the Notch1 ligand Jagged-1 in rats with MI reduced cardiac fibrosis ([@B4]). Moreover, augmentation of Notch3 expression by lentiviral transfection inhibited fibroblast--myofibroblast transition both in TGF-β1-treated cardiac fibroblasts *in vitro* and in mice with MI, minimizing cardiac fibrosis ([@B37]). As previously mentioned, Notch signaling can inhibit EMT ([@B39]; [@B15]), which also contributes to cardiac fibrosis ([@B35]). This point, however, remains controversial: indeed, in Notch transgenic mice undergoing MI and pressure overload, Notch induced epicardial cells to undergo EMT and generate a multipotent stromal cell population capable of differentiating into fibroblasts and producing reparative fibrosis ([@B28]).

The main identified mechanism by which Notch signaling interferes with myofibroblast differentiation consists in its ability to antagonize TGF-β/Smad3 signaling, the key intracellular pathway promoting cell activation and fibrogenesis ([@B37]; [@B34]) (**Figure [2](#F2){ref-type="fig"}**).
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Targeting the Notch pathway may be a meaningful therapeutic strategy for cardiac fibrosis. In this context, the hormone relaxin, known as anti-fibrotic agent and under clinical investigation in heart failure patients ([@B23]), was shown to inhibit the TGF-β1/Smad3 axis and to counteract TGF-β1-induced transition of neonatal cardiac stromal cells and NIH3T3 fibroblasts to myofibroblasts acting *via* the up-regulation of Notch1 signaling ([@B30]; [@B32]; [@B39]).

Conclusion
==========

The Notch pathway is pivotal in the protection and healing of the ischemic heart because it regulates key mechanisms of myocardial resistance to ischemia and controls the balance between fibrotic and regenerative repair. Targeting Notch signaling, for example by soluble Notch ligands or Notch pathway activating molecules delivered intramyocardially or embedded into suitable biomaterials ([@B10]; [@B20]; [@B2]; [@B4]), may be a worthwhile therapeutic approach to cardiovascular disease.
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